TSC2 genetic variant and prognosis in non-small cell lung cancer after curative surgery.
Yong Hoon LeeSook Kyung DoShin Yup LeeHyo-Gyoung KangJin Eun ChoiMi Jeong HongJang Hyuck LeeEung Bae LeeJi Yun JeongKyung Min ShinWon Kee LeeYangki SeokSukki ChoSeung Soo YooJaehee LeeSeung Ick ChaChang Ho KimSanghoon JheonJae Yong ParkPublished in: Thoracic cancer (2018)
This study was conducted to investigate the associations between polymorphisms of genes involved in the LKB1 pathway and the prognosis of patients with non-small cell lung cancer (NSCLC) after surgical resection. Twenty-three single nucleotide polymorphisms (SNPs) in the LKB1 pathway were investigated in 782 patients with NSCLC who underwent curative surgery. The association of SNPs with overall survival (OS) and disease-free survival (DFS) were analyzed. Among the 23 SNPs investigated, TSC2 rs30259G > A was associated with significantly worse OS and DFS (adjusted hazard ratio for OS 1.88, 95% confidence interval 1.21-2.91, P = 0.005; adjusted hazard ratio for DFS 1.65, 95% confidence interval 1.15-2.38, P = 0.01, under codominant models, respectively). Subgroup analysis showed that SNPs were significantly associated with survival outcomes in squamous cell carcinoma, ever-smokers, and stage I, but not in adenocarcinoma, never-smokers, and stage II-IIIA. The results suggest that TSC2 rs30259G > A may be useful to predict prognosis in patients with NSCLC, especially squamous cell carcinoma, after curative surgery.
Keyphrases
- squamous cell carcinoma
- genome wide
- minimally invasive
- free survival
- small cell lung cancer
- coronary artery bypass
- advanced non small cell lung cancer
- rectal cancer
- locally advanced
- surgical site infection
- smoking cessation
- prognostic factors
- lymph node metastasis
- randomized controlled trial
- clinical trial
- brain metastases
- epidermal growth factor receptor
- acute coronary syndrome